WALTHAM, Mass.– Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced it has completed the acquisition of Sanofi’s sterile fill-finish and packaging site in Ridgefield, New Jersey. The move expands the companies’ strategic partnership and increases Thermo Fisher’s U.S. drug product manufacturing capacity. Terms of the transaction were not disclosed.
The Ridgefield site, now part of Thermo Fisher’s pharma services business within its Laboratory Products and Biopharma Services segment, will continue to produce a portfolio of therapies for Sanofi. Thermo Fisher also plans to leverage the facility to meet growing demand for domestic manufacturing from pharmaceutical and biotech customers.
“We are excited to add Sanofi’s Ridgefield site to our network and welcome more than 200 highly experienced colleagues to Thermo Fisher,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher. “Bringing this world-class facility and team into our network strengthens our U.S. manufacturing capabilities to better support pharmaceutical and biotech customers, while positioning us for future expansion.”
Thermo Fisher operates one of the largest global sterile fill-finish manufacturing networks and now adds Ridgefield to its U.S. sites in Greenville, North Carolina, and Plainville, Massachusetts. These facilities play a central role in the company’s Accelerator™ Drug Development 360° CDMO and CRO solutions, designed to help emerging biotech and biopharma companies speed life-changing medicines to patients.
